Study Stopped
Due to inability to get support for the study
Bronchoscopy vs. Clinical Pulmonary Infection Score Guided Approach in Suspected Ventilator-Associated Pneumonia (VAP)
Bronchoscopy Versus Clinical Pulmonary Infection Score Guided Approach in Suspected Ventilator-Associated Pneumonia (VAP): Randomized Clinical Trial
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
The reported incidence of ventilator associated pneumonia (VAP) is 10 to 15 per 1,000 ventilator days. VAP leads to an excess cost exceeding $40,000 per patient and is associated with a crude mortality rate as high as 76%. The clinical criteria for the diagnosis of VAP have low specificity and may lead to unnecessary antibiotic use. The Clinical Pulmonary Infection Score (CPIS) and bronchoscopic approaches lower unnecessary antimicrobial use, antimicrobial resistance, and superinfection compared to the traditional clinical criteria. Based on the available evidence and local microbiology data, we have developed a VAP management protocol guided by CPIS or bronchoalveolar lavage (BAL) in adults with suspected VAP. These two approaches have not been compared against each other. Although the diagnostic studies in the CPIS guided approach are inexpensive and easily available, BAL has the potential to minimize the unnecessary use of antibiotics and reduce the development of drug resistant pathogens. In this study, we propose to test the hypothesis that BAL leads to a reduction in antibiotic use compared to CPIS in patients with suspected VAP. The study design will be a randomized, clinical trial comparing CPIS versus BAL. The primary outcome measure will be antibiotic utilization. The secondary outcome measures will be mortality, morbidity, development of resistant pathogens and superinfection and infection related financial burden. Completion of this trial will help us identify the best approach to avoid unnecessary antibiotic utilization and minimize the development of resistant pathogens (with their associated morbidity and mortality) in critically ill patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Jan 2007
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2007
CompletedFirst Submitted
Initial submission to the registry
December 22, 2007
CompletedFirst Posted
Study publicly available on registry
January 8, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2009
CompletedSeptember 26, 2023
September 1, 2023
2.3 years
December 22, 2007
September 25, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
14-day antibiotic free days
Day 14 of enrolment
Secondary Outcomes (3)
Mortality
28 days
Daily organ failure score
14 days
Length of hospital stay
Hospital stay
Study Arms (2)
1
ACTIVE COMPARATORBronchoscopy
2
ACTIVE COMPARATORCPIS
Interventions
Eligibility Criteria
You may qualify if:
- Age \>= 18 years
- Endotracheal intubation
- Suspected VAP with:
- New or progressive pulmonary infiltrates plus two of the following (In patients with pre-existing ALI or ARDS, physicians' suspicion of VAP with two of the listed criteria will be used.): Temperature \> 38 C or \< 36 C, WBC \> 12,000/mL or \< 4,000/mL, purulent endotracheal secretions.
- Patient or legally authorized representative is able to sign Informed Consent
You may not qualify if:
- Prison inmates
- Immunocompromised patients
- Participation in another trial conflicting with the design of the current trial
- Previous history of VAP during the same hospitalization
- Previous participation in the current study
- Concomitant non-pulmonary infection diagnosed within 3 days preceding the suspected VAP
- Patient's primary care provider does not want subject to be enrolled in the study
- Contraindications for bronchoscopy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
Related Publications (1)
Afessa B, Hubmayr RD, Vetter EA, Keegan MT, Swanson KL, Baddour LM, Cockerill FR 3rd, Peters SG. Bronchoscopy in ventilator-associated pneumonia: agreement of calibrated loop and serial dilution. Am J Respir Crit Care Med. 2006 Jun 1;173(11):1229-32. doi: 10.1164/rccm.200512-1899OC. Epub 2006 Mar 9.
PMID: 16528014BACKGROUND
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bekele Afessa, MD
Mayo Clinic
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 22, 2007
First Posted
January 8, 2008
Study Start
January 1, 2007
Primary Completion
May 1, 2009
Study Completion
May 1, 2009
Last Updated
September 26, 2023
Record last verified: 2023-09